http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3428286-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91fca07cdbc15d3f78a73cd9ad73c831 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e5fbdb2b31c9d7af515b9aa72d68221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14526b2cf00a6a8ba4a414b5e0989ecd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a534967a8855648ed438c0255047933 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5066d441dcacd76d9f60d6bb58c5ccf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3a529dd3d2a9553e637f7009054d2a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8391afd15e1420ba2aee2d70cd4a1877 |
| publicationDate | 2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3428286-A1 |
| titleOfInvention | Predictive test of anti-tnf alpha response in patients with an inflammatory disease |
| abstract | The present invention relates to an ex vivo method for predicting anti-TNF alpha response in a patient with an inflammatory disease in which this treatment is generally indicated, comprising the steps of: na) Measuring, before any anti-TNF alpha treatment, the level L M of Burkholderiales in a patient stool sample, and nb) Calculating the score S1=L M /L ref , nWherein: n¢ If S1 > 1, the patient is considered likely to have a clinical response to an anti-TNF alpha treatment, or, If S1 ¤ 1, the patient is considered unlikely to have a clinical response to an anti-TNF alpha treatment. It also relates to an ex vivo method for predicting anti-TNF alpha response in a patient with an inflammatory disease in which this treatment is generally indicated, and to the use of at least one bacteria selected from the group comprising Burkholderiales, Serratia marcescens, Klebsiella oxytoca, Enterococcus gallinarum, Weissella cibaria and Coprococcus eutactus, as a predictive biomarker of the clinical outcome of an anti-TNF alpha treatment in an inflammatory disease. |
| priorityDate | 2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 236.